Moderna (NASDAQ:MRNA) has slid 4.8% after a Stat News report saying a trial of the company’s COVID-19 vaccine has been delayed.
The 30,000-patient Phase 3 study was set to begin July 9, but changes to the protocol are pushing back the expected start. It could still come in July as the company looks “close to being on target,” according to one investigator.
The delay is a potential hurdle in the company’s ambitious plan to have key data by Thanksgiving, Stat News notes.
For now, Pfizer (PFE +2.7%) and BioNTech plan to start a 30,000-patient study of their own later this month; AstraZeneca (AZN +0.6%) and Oxford will start a similar-size trial in August; and Johnson & Johnson (JNJ +0.4%) in September.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.